OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation

Core Insights - OSE Immunotherapeutics has announced a new three-year strategic plan aimed at accelerating the development of its promising programs while ensuring financial discipline [1][3] - The plan focuses on creating multiple near-term catalysts and emphasizes the company's commitment to immunology innovation [1][3] Value Creation Opportunities - The strategy includes advancing one or two specialty indications and a subcutaneous formulation for Lusvertikimab, enhancing its value proposition and opening new business opportunities [3][4] - The company aims to complete the Tedopi Phase 3 trial in Non-Small Cell Lung Cancer (NSCLC) with limited additional financial resources, expecting a futility analysis in Q3 2026 and a full read-out in Q1 2028 [8] - Development of Lusvertikimab in one or two new rare/specialty indications is planned, utilizing the existing intravenous formulation to target diseases with high unmet medical needs [8] - A pivot to a subcutaneous formulation of Lusvertikimab for Ulcerative Colitis (UC) is underway, with the goal of partnering this asset once bioequivalence data is generated [8] - The company will maintain scientific leadership by leveraging its research engine to fuel innovation and optimize intellectual property management [8] Financial Strategy - OSE Immunotherapeutics aims to limit shareholder dilution while securing a reasonable cash runway through a mix of financing options, including equity and new debt [9] - The company currently has financial visibility until early Q4 2026, excluding additional financing or milestone payments from partnerships [9][10] - The strategic plan requires significantly less investment than the previously planned Phase 2b for Lusvertikimab IV in UC, although additional financial resources will still be necessary [9] Future Developments - The company is exploring new strategic partnerships for its proprietary assets and may receive milestone payments, such as a EUR 17.5 million payment from Boehringer Ingelheim related to a future acquisition [10] - Other proprietary assets will continue to advance in preclinical development at limited cost to maximize partnership opportunities [11]